Markets and share prices

Gilead Sciences Inc

09 Sep 2025 23:43 PM

20 minutes delayed

Value/last trade

115.76 USD

-0.10%

-0.12

Day high/low

116.25 - 113.87

Ex-Dividend Date

15 Sep 2025

Dividend Pay Date

29 Sep 2025

Rolling 12m Net Div

0.79

NASDAQ

Gilead Sciences Inc

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

© Morningstar. All Rights Reserved. The information, data, analyses and opinions contained herein (1) include the confidential and proprietary information of Morningstar, and/or its content providers; (2) may include, or be derived from, account information provided by your financial advisor which cannot be verified by Morningstar; (3) may not be copied or redistributed; (4) do not constitute investment advice offered by Morningstar; (5) are provided solely for informational purposes and therefore are not an offer or recommendation to buy or sell a security; and (6) are not warranted to be correct, complete or accurate. Except as otherwise required by law, Morningstar shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, this information, data, analyses or opinions or their use.

Warning: Past performance is not a reliable guide to future performance. The value of investments and of any income derived from them may go down as well as up. You may not get back all of your original investment. Returns on investments may increase or decrease as a result of currency fluctuations.